NeuroBo Pharmaceuticals, Inc. (NRBO) announced on Thursday that the FDA has approved its Investigational New Drug or IND application for DA-1726, a new dual oxyntomodulin analog agonist.
Stock of NeuroBo Pharmaceuticals, Inc. (NRBO) gained 48 percent on Thursday after the FDA approved the company's Investigational New Drug or IND application for DA-1726, a new dual oxyntomodulin analog agonist.
NeuroBo Pharmaceuticals, Inc. (NRBO), a clinical-stage biotechnology company, Thursday said it has submitted Investigational New Drug or IND application to FDA, regarding Phase 1 clinical trial of DA-1726 for the treatment of obesity.